{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-000823","form_type":"8-K","ticker":"XLO","cik":"0001840233","company_name":"Xilio Therapeutics, Inc.","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.209453+00:00","generated_at":"2026-05-26T23:00:08.068336+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Xilio signs AbbVie deal: $52M upfront, up to $2.1B milestones for masked T-cell engagers","bullets":["Upfront $52M ($42M cash + $10M equity at $2.30/shr); AbbVie gets options for 4 masked TCE programs and license for masked antibody.","Contingent payments up to ~$2.1B in option fees and milestones plus tiered mid-to-high single-digit royalties.","Xilio announces three wholly-owned preclinical masked TCE programs targeting PSMA, CLDN18.2, STEAP1 with candidate nomination timelines through 2027.","Cash runway extended into Q1 2026 with upfront payments; additional milestones require further capital.","Collaboration validates Xilio's tumor-activation platform; CEO highlights potential to improve TCE tolerability."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-000823","json":"https://secwatch.observer/filing/0001558370-25-000823.json","markdown":"https://secwatch.observer/filing/0001558370-25-000823.md","text":"https://secwatch.observer/filing/0001558370-25-000823.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840233/000155837025000823/0001558370-25-000823-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840233/000155837025000823/xlo-20250210x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:00:08.068336+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}